Role of GSTP1-1 in mediating the effect of As2O3 in the Acute Promyelocytic Leukemia cell line NB4.

Abstract:

:Arsenic trioxide (As2O3) is a highly effective agent in the treatment of acute promyelocytic leukemia (APL), whereas other hematopoietic tumors are less responsive to this agent and mechanisms underlying As2O3,-resistance are poorly understood. To better understand the complex network of GSH-related pathways in As2O3 sensitivity, we investigated the role of GSH and GSH-relevant enzymes in an APL cell line sensitive to As2O3 (NB4) and in a resistant subclone (AsR). Cell proliferation, viability, and apoptosis were investigated in NB4 cells before and after treatment with 1 muM As2O3 and in AsR cells. In these experimental cell models, GSTP1-1, JNK1 and JNK2 proteins were analyzed by immunoblotting, and a kinase assay for JNK1 was performed. GSH levels as well as the activities of the enzymes glutathione peroxidase, glutathione transferase, gamma-Glutamylcysteynilsinthetase and superoxide dismutase were measured. NB4 cells treated with As2O3 showed a high level of oxidative stress and an increase of GSH levels. GSTP1-1 polymerization and JNK1 activation were detectable after 24 h and were followed by an increase of the apoptotic rate starting at 72 h. Neither GSTP1-1 polymerization nor JNK activation was found in AsR cells that showed a very low apoptotic rate. Our results suggest that APL sensitivity to As2O3 might be, at least in part, mediated by the balance between association and dissociation of JNK from GSTP1-1, depending on the redox status of the cell. Further investigation is warranted to find a way to interfere with this balance, whenever it might represent a mechanism of drug resistance.

journal_name

Ann Hematol

journal_title

Annals of hematology

authors

Bernardini S,Nuccetelli M,Noguera NI,Bellincampi L,Lunghi P,Bonati A,Mann K,Miller WH Jr,Federici G,Lo Coco F

doi

10.1007/s00277-006-0139-8

subject

Has Abstract

pub_date

2006-10-01 00:00:00

pages

681-7

issue

10

eissn

0939-5555

issn

1432-0584

journal_volume

85

pub_type

杂志文章
  • Identification of CD318 (CDCP1) as novel prognostic marker in AML.

    abstract::Genetic and morphological markers are well-established prognostic factors in acute myeloid leukemia (AML). However, further reliable markers are urgently needed to improve risk stratification in AML. CD318 (CDCP1) is a transmembrane protein which in solid tumors promotes formation of metastasis and correlates with poo...

    journal_title:Annals of hematology

    pub_type: 杂志文章

    doi:10.1007/s00277-020-03907-9

    authors: Heitmann JS,Hagelstein I,Hinterleitner C,Roerden M,Jung G,Salih HR,Märklin M,Kauer J

    更新日期:2020-03-01 00:00:00

  • Histone deacetylase inhibitor prevents cell growth in Burkitt's lymphoma by regulating PI3K/Akt pathways and leads to upregulation of miR-143, miR-145, and miR-101.

    abstract::Burkitt lymphoma (BL) is an aggressive B-cell lymphoma more common in children comprising one third of pediatric non-Hodgkin lymphoma cases. The recent discovery in BL pathogenesis highlighted the activation of PI3K pathway in cooperation with Myc in the development of BL. In this study, we demonstrated that PI3K/Akt ...

    journal_title:Annals of hematology

    pub_type: 杂志文章

    doi:10.1007/s00277-014-2021-4

    authors: Ferreira AC,Robaina MC,Rezende LM,Severino P,Klumb CE

    更新日期:2014-06-01 00:00:00

  • High-dose therapy and stem cell transplantation in follicular lymphoma.

    abstract::Indolent follicular lymphomas are diseases which are generally incurable with conventional therapy. Although patients can survive for prolonged periods, the median duration of first remissions is about 2.5 years, and subsequent remissions progressively shorten with time. High-dose therapy with hematopoietic stem cell ...

    journal_title:Annals of hematology

    pub_type: 杂志文章,评审

    doi:10.1007/s002770050503

    authors: Friedberg JW,Freedman AS

    更新日期:1999-05-01 00:00:00

  • Good adherence to imatinib therapy among patients with chronic myeloid leukemia--a single-center observational study.

    abstract::Previous studies have suggested that adherence to imatinib therapy can be an obstacle among patients with chronic myeloid leukemia (CML). We studied adherence to imatinib therapy among CML patients treated at the Sahlgrenska University Hospital. We identified all CML patients that were alive at the 1st of January 2010...

    journal_title:Annals of hematology

    pub_type: 杂志文章

    doi:10.1007/s00277-011-1359-0

    authors: Jönsson S,Olsson B,Söderberg J,Wadenvik H

    更新日期:2012-05-01 00:00:00

  • Clinical characteristics and prognosis of immunoglobulin D myeloma in the novel agent era.

    abstract::Immunoglobulin D (IgD) myeloma is a rare subtype that used to lead to a poor outcome. To investigate the current clinical features, cytogenetic changes and survival of patients with IgD myeloma under novel treatments, we analysed 47 patients with IgD myeloma, 31 men and 16 women, with a median age of 54.5 years. We fo...

    journal_title:Annals of hematology

    pub_type: 杂志文章

    doi:10.1007/s00277-018-3582-4

    authors: Chen L,Fan F,Deng J,Xu J,Xu A,Sun C,Hu Y

    更新日期:2019-04-01 00:00:00

  • Risk for cytomegalovirus infection following reduced intensity allogeneic stem cell transplantation.

    abstract::Preliminary data suggest a faster immune recovery following non-myeloablative stem cell transplantation because of the persistence of recipient T cells, but the real impact on post-transplant infectious complications remains unknown. We retrospectively analysed the incidence of cytomegalovirus (CMV) infection in twent...

    journal_title:Annals of hematology

    pub_type: 杂志文章

    doi:10.1007/s00277-003-0706-1

    authors: Nachbaur D,Larcher C,Kircher B,Eibl G,Nussbaumer W,Gunsilius E,Haun M,Grünewald K,Gastl G

    更新日期:2003-10-01 00:00:00

  • The proteasome inhibitor bortezomib targets cell cycle and apoptosis and acts synergistically in a sequence-dependent way with chemotherapeutic agents in mantle cell lymphoma.

    abstract::Single-agent bortezomib, a potent, selective, and reversible inhibitor of the 26S proteasome, has demonstrated clinical efficacy in relapsed and refractory mantle cell lymphoma (MCL). Objective response is achieved in up to 45% of the MCL patients; however, complete remission rates are low and duration of response pro...

    journal_title:Annals of hematology

    pub_type: 杂志文章

    doi:10.1007/s00277-011-1377-y

    authors: Hutter G,Rieken M,Pastore A,Weigert O,Zimmermann Y,Weinkauf M,Hiddemann W,Dreyling M

    更新日期:2012-06-01 00:00:00

  • Novel treatment strategies in follicular lymphoma.

    abstract::Malignant lymphomas are a heterogenous group of malignancies, belonging to the 10 most frequent types of cancers worldwide. In indolent lymphoma only patients with limited stage I/II (Ann Arbor) can be potentially cured by local irradiation. However, about 85% of cases present with advanced stage; for these patients n...

    journal_title:Annals of hematology

    pub_type: 杂志文章

    doi:10.1007/s00277-004-0850-2

    authors: Buske C,Dreyling H,Unterhalt M,Hiddemann W

    更新日期:2004-01-01 00:00:00

  • Reduced-intensity haploidentical peripheral blood stem cell transplantation using low-dose thymoglobulin for aggressive adult T cell leukemia/lymphoma patients in non-complete remission.

    abstract::Haploidentical hematopoietic stem cell transplantation (haplo-HSCT) has been accepted as a treatment option for aggressive (acute or lymphoma type) adult T cell leukemia/lymphoma (ATLL) patients with a poor prognosis, when a suitable HLA-matched donor is not available. However, haplo-HSCT carries a potential risk of t...

    journal_title:Annals of hematology

    pub_type: 临床试验,杂志文章

    doi:10.1007/s00277-020-03934-6

    authors: Hirosawa M,Yamaguchi T,Tanaka A,Kominato Y,Higashi T,Morimoto H,Tsukada J

    更新日期:2020-03-01 00:00:00

  • Prognostic value of cytogenetics in adult patients with Philadelphia-negative acute lymphoblastic leukemia.

    abstract::The prognostic value of cytogenetics in adult acute lymphoblastic leukemia (ALL) is not as established as in childhood ALL. We have analyzed the outcome and prognostic value of karyotype in 84 adults diagnosed with Philadelphia-negative ALL from a single institution that received induction chemotherapy and had success...

    journal_title:Annals of hematology

    pub_type: 杂志文章

    doi:10.1007/s00277-011-1331-z

    authors: Gómez-Seguí I,Cervera J,Such E,Martínez-Cuadrón D,Luna I,Ibáñez M,López-Pavía M,Gascón A,Roig M,Martínez J,Sanz J,Montesinos P,Martín-Aragonés G,Lorenzo I,Senent L,Barragán E,Cordón L,Sempere A,Sanz GF,Sanz MA

    更新日期:2012-01-01 00:00:00

  • Neutropenic enterocolitis in acute leukemia: diagnostic and therapeutic dilemma.

    abstract::The main purpose of this report is to focus on the importance of an accurate etiologic diagnosis of gastrointestinal complications during chemotherapy for acute myeloid leukemia, taking into account that a syndrome characterized by bowel wall thickening associated with diarrhea and abdominal pain may have etiologies d...

    journal_title:Annals of hematology

    pub_type: 杂志文章

    doi:10.1007/s00277-003-0755-5

    authors: Capria S,Vitolo D,Cartoni C,Dessanti L,Micozzi A,Mandelli F,Meloni G

    更新日期:2004-03-01 00:00:00

  • Hematopoietic stem cell mobilization with the reversible CXCR4 receptor inhibitor plerixafor (AMD3100)-Polish compassionate use experience.

    abstract::Recent developments in the field of targeted therapy have led to the discovery of a new drug, plerixafor, that is a specific inhibitor of the CXCR4 receptor. Plerixafor acts in concert with granulocyte colony-stimulating factor (G-CSF) to increase the number of stem cells circulating in the peripheral blood (PB). Ther...

    journal_title:Annals of hematology

    pub_type: 杂志文章

    doi:10.1007/s00277-010-1098-7

    authors: Basak GW,Knopinska-Posluszny W,Matuszak M,Kisiel E,Hawrylecka D,Szmigielska-Kaplon A,Urbaniak-Kujda D,Dybko J,Zielinska P,Dabrowska-Iwanicka A,Werkun J,Rzepecki P,Wroblewska W,Wiktor-Jedrzejczak W

    更新日期:2011-05-01 00:00:00

  • Ruxolitinib in clinical practice for primary and secondary myelofibrosis: an analysis of safety and efficacy of Gruppo Laziale of Ph-negative MPN.

    abstract::Ruxolitinib, a JAK1 and JAK2 inhibitor, has been tested and approved for the treatment of primary and secondary myelofibrosis (MF). Aim of our study is to report safety and efficacy of ruxolitinib in 98 patients affected by MF treated outside clinical trials and collected and treated consecutively by the Lazio Coopera...

    journal_title:Annals of hematology

    pub_type: 杂志文章,多中心研究

    doi:10.1007/s00277-016-2884-7

    authors: Breccia M,Andriani A,Montanaro M,Abruzzese E,Buccisano F,Cedrone M,Centra A,Villivà N,Celesti F,Trawinska MM,Massaro F,Di Veroli A,Anaclerico B,Colafigli G,Molica M,Spadea A,Petriccione L,Cimino G,Latagliata R

    更新日期:2017-03-01 00:00:00

  • Lymphoma-like monoclonal B cell lymphocytosis in a patient population: biology, natural evolution, and differences from CLL-like clones.

    abstract::High-count monoclonal B cell lymphocytosis (MBL) with a chronic lymphocytic leukemia (CLL) phenotype is a well-known entity, featuring 1-4% annual risk of progression towards CLL requiring treatment. Lymphoma-like MBL (L-MBL), on the other hand, remains poorly defined and data regarding outcome are lacking. We retrosp...

    journal_title:Annals of hematology

    pub_type: 杂志文章

    doi:10.1007/s00277-018-3282-0

    authors: Vander Meeren S,Heyrman B,Renmans W,Bakkus M,Maes B,De Raeve H,Schots R,Jochmans K

    更新日期:2018-07-01 00:00:00

  • Development of a disease-specific quality of life questionnaire for patients with aplastic anemia and/or paroxysmal nocturnal hemoglobinuria (QLQ-AA/PNH)-report on phases I and II.

    abstract::Acquired aplastic anemia (AA) and paroxysmal nocturnal hemoglobinuria (PNH) are interrelated ultra-rare diseases. Quality of life (QoL) evaluation tools used in studies for AA and PNH are unspecific and designed for cancer patients (e.g., the European Organization for Research and Treatment of Cancer Quality of Life Q...

    journal_title:Annals of hematology

    pub_type: 杂志文章

    doi:10.1007/s00277-016-2867-8

    authors: Groth M,Singer S,Niedeggen C,Petermann-Meyer A,Röth A,Schrezenmeier H,Höchsmann B,Brümmendorf TH,Panse J

    更新日期:2017-02-01 00:00:00

  • Reduced frequency treatment with bortezomib plus dexamethasone for elderly patients with relapsed and/or refractory multiple myeloma: a phase 2 study of the Japanese Myeloma Study Group (JMSG-0902).

    abstract::Bortezomib is one of the most widely used novel drugs for the treatment of multiple myeloma (MM). However, twice-weekly intravenous administration is associated with innegligible adverse events and treatment discontinuation. We therefore evaluated the long-term efficacy and feasibility of reduced frequency treatment w...

    journal_title:Annals of hematology

    pub_type: 杂志文章,多中心研究

    doi:10.1007/s00277-016-2661-7

    authors: Ozaki S,Hata H,Abe M,Saitoh T,Hanamura I,Yano H,Sunami K,Kosugi H,Sawamura M,Nakazato T,Masunari T,Mori M,Takagi T,Murakami H,Shimizu K

    更新日期:2016-05-01 00:00:00

  • Improved clinical outcomes for multiple myeloma patients treated at a single specialty clinic.

    abstract::Despite recent advances made in its treatment, multiple myeloma (MM) remains an incurable B cell malignancy. Thus, the objective for treating these patients is to prolong overall survival (OS) and preserve patients' quality of life. We have analyzed data from 264 consecutive MM patients who had their initial visit bet...

    journal_title:Annals of hematology

    pub_type: 杂志文章

    doi:10.1007/s00277-016-2888-3

    authors: Berenson A,Vardanyan S,David M,Wang J,Harutyunyan NM,Gottlieb J,Halleluyan R,Spektor TM,Udd KA,Eshaghian S,Nassir Y,Eades B,Swift R,Berenson JR

    更新日期:2017-03-01 00:00:00

  • Successful transplantation and engraftment of peripheral blood stem cells after cryopreservation, positive and negative purging procedures, and a second cryopreservation cycle.

    abstract::Transplantation of peripheral blood stem cells (PBSC), positively and/or negatively selected immediately after harvest, has become a widely applied therapeutic option in hematological or oncological patients. The following case of peripheral blood stem cell transplantation represents the first case of successful trans...

    journal_title:Annals of hematology

    pub_type: 杂志文章

    doi:10.1007/s002770000243

    authors: Humpe A,Riggert J,Wolf C,Binder C,Köhler M

    更新日期:2001-02-01 00:00:00

  • Early CMV replication and subsequent chronic GVHD have a significant anti-leukemic effect after allogeneic HSCT in acute myeloid leukemia.

    abstract::Early cytomegalovirus (CMV) replication (eCMV) after allogeneic hematopoietic stem cell transplantation (allo-HSCT) has been suggested as an independent factor that reduces leukemia relapse risk. We retrospectively analyzed 74 patients with acute myeloid leukemia (AML) who underwent allo-HSCT between August 2006 and S...

    journal_title:Annals of hematology

    pub_type: 杂志文章

    doi:10.1007/s00277-014-2190-1

    authors: Jang JE,Kim SJ,Cheong JW,Hyun SY,Kim YD,Kim YR,Kim JS,Min YH

    更新日期:2015-02-01 00:00:00

  • Mucocutaneous autoimmune syndrome following fludarabine therapy for low-grade non-Hodgkin's lymphoma of B-cell type (B-NHL).

    abstract::A 40-year-old patient with low-grade B-NHL developed a generalized macular-papular rash following the first cycle of fludarabine treatment which progressed to a complete epidermal necrolysis following the second cycle. Clinical symptoms and the results of the direct and indirect immunofluorescence were consistent with...

    journal_title:Annals of hematology

    pub_type: 杂志文章

    doi:10.1007/s002770050347

    authors: Braess J,Reich K,Willert S,Strutz F,Neumann C,Hiddemann W,Wörmann B

    更新日期:1997-11-01 00:00:00

  • Cationic lipid mediated transfer of c-abl and bcr antisense oligonucleotides to immature normal myeloid cells: uptake, biological effects and modulation of gene expression.

    abstract::Uptake and biochemical and biological effects of antisense oligodeoxynucleotides (ODN) specific for c-abl and bcr genes were studied in normal immature myeloid cells. CD34-positive cells were purified by positive and negative selection and cultured in liquid culture for 7 days. These cells were then incubated with ODN...

    journal_title:Annals of hematology

    pub_type: 杂志文章

    doi:10.1007/BF00641311

    authors: Albrecht T,Schwab R,Peschel C,Engels HJ,Fischer T,Huber C,Aulitzky WE

    更新日期:1996-02-01 00:00:00

  • Allogeneic bone marrow transplantation compared to peripheral blood stem cell transplantation for the treatment of hematologic malignancies: a meta-analysis based on time-to-event data from randomized controlled trials.

    abstract::Controversy remains regarding the transplant outcomes of human leukocyte antigen-identical related bone marrow transplantation (BMT) and peripheral blood stem cell transplantation (PBSCT) for the treatment of patients with hematological malignancies. To provide an estimate of the effect of BMT and PBSCT on clinical ou...

    journal_title:Annals of hematology

    pub_type: 杂志文章,meta分析

    doi:10.1007/s00277-011-1299-8

    authors: Chang YJ,Weng CL,Sun LX,Zhao YT

    更新日期:2012-03-01 00:00:00

  • Role of radiography, MRI and FDG-PET/CT in diagnosing, staging and therapeutical evaluation of patients with multiple myeloma.

    abstract::Multiple myeloma is a malignant B-cell neoplasm that involves the skeleton in approximately 80% of the patients. With an average age of 60 years and a 5-years survival of nearly 45% Brenner et al. (Blood 111:2516-2520,35) the onset is to be classified as occurring still early in life while the disease can be very aggr...

    journal_title:Annals of hematology

    pub_type: 杂志文章,评审

    doi:10.1007/s00277-009-0829-0

    authors: Lütje S,de Rooy JW,Croockewit S,Koedam E,Oyen WJ,Raymakers RA

    更新日期:2009-12-01 00:00:00

  • New prognostic model for extranodal natural killer/T cell lymphoma, nasal type.

    abstract::Extranodal natural killer/T cell lymphoma, nasal type (ENKTL) is an aggressive disease with a poor prognosis, requiring risk stratification in affected patients. We designed a new prognostic model specifically for ENKTL to identify high-risk patients who need more aggressive therapy. We retrospectively reviewed 158 pa...

    journal_title:Annals of hematology

    pub_type: 杂志文章

    doi:10.1007/s00277-014-2089-x

    authors: Cai Q,Luo X,Zhang G,Huang H,Huang H,Lin T,Jiang W,Xia Z,Young KH

    更新日期:2014-09-01 00:00:00

  • A review of the European LeukemiaNet recommendations for the management of CML.

    abstract::Several guidelines and recommendations on the management of chronic myeloid leukemia (CML) have been prepared by several scientific societies. The European LeukemiaNet (ELN) appointed a panel of experts who submitted their recommendations to peer-reviewed scientific journals in 2006, 2009, and 2013. Here, we make a cr...

    journal_title:Annals of hematology

    pub_type: 杂志文章,评审

    doi:10.1007/s00277-015-2322-2

    authors: Baccarani M,Castagnetti F,Gugliotta G,Rosti G

    更新日期:2015-04-01 00:00:00

  • Cytogenetic features and prognosis analysis in Chinese patients with myelodysplastic syndrome: a multicenter study.

    abstract::It has been suggested that Asian and Western myelodysplastic syndrome (MDS) patients have different cytogenetic and prognostic features. In this study, we retrospectively analyzed clinical and cytogenetic data from 435 Chinese adult primary MDS patients. In addition, we evaluated the prognostic value of the World Heal...

    journal_title:Annals of hematology

    pub_type: 杂志文章,多中心研究

    doi:10.1007/s00277-009-0861-0

    authors: Wang H,Wang X,Xu X,Lin G

    更新日期:2010-06-01 00:00:00

  • Chemotherapy-induced mesenchymal stem cell damage in patients with hematological malignancy.

    abstract::Hematopoietic recovery after high-dose chemotherapy (HDC) in the treatment of hematological diseases may be slow and/or incomplete. This is generally attributed to progressive hematopoietic stem cell failure, although defective hematopoiesis may be in part due to poor stromal function. Chemotherapy is known to damage ...

    journal_title:Annals of hematology

    pub_type: 临床试验,杂志文章

    doi:10.1007/s00277-009-0896-2

    authors: Kemp K,Morse R,Wexler S,Cox C,Mallam E,Hows J,Donaldson C

    更新日期:2010-07-01 00:00:00

  • Clinicopathological features of primary splenic follicular lymphoma.

    abstract::Follicular lymphoma (FL) is a low-grade lymphoma that is usually characterized by generalized lymphadenopathy. Extranodal invasion by FL generally involves the bone marrow, skin, and duodenum; splenic infiltration often occurs in the advanced stages. However, primary splenic FL is very rare. Hence, few studies have be...

    journal_title:Annals of hematology

    pub_type: 临床试验,杂志文章

    doi:10.1007/s00277-017-3139-y

    authors: Shimono J,Miyoshi H,Kamimura T,Eto T,Miyagishima T,Sasaki Y,Kurita D,Kawamoto K,Nagafuji K,Seto M,Teshima T,Ohshima K

    更新日期:2017-12-01 00:00:00

  • Platelet activation and function during eltrombopag treatment in immune thrombocytopenia.

    abstract::We monitored platelet activation by means of P-selectin and platelet monocyte aggregates (PMA) and platelet function by whole blood multiple electrode aggregometry and platelet adhesion under high shear in chronic immune thrombocytopenia patients to define changes in platelet activation during treatment with eltrombop...

    journal_title:Annals of hematology

    pub_type: 杂志文章,随机对照试验

    doi:10.1007/s00277-011-1249-5

    authors: Haselboeck J,Pabinger I,Ay C,Koder S,Panzer S

    更新日期:2012-01-01 00:00:00

  • The role of cytokines and hematopoietic growth factors in the autocrine/paracrine regulation of inducible hematopoiesis.

    abstract::To elucidate the role of hematopoietic growth factors (HGFs) and other cytokines in the autocrine or paracrine regulation of inducible hematopoiesis we studied cytokine gene expression in the bone marrow (BM) of patients after myelosuppressive treatment. Furthermore, we studied the cytokine gene expression profile in ...

    journal_title:Annals of hematology

    pub_type: 杂志文章

    doi:10.1007/s002770050308

    authors: Cluitmans FH,Esendam BH,Veenhof WF,Landegent JE,Willemze R,Falkenburg JH

    更新日期:1997-07-01 00:00:00